BH.IMMUN&BIO | LUPIN | BH.IMMUN&BIO/ LUPIN |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -7.6 | 39.1 | - | View Chart |
P/BV | x | 1.5 | 6.1 | 24.4% | View Chart |
Dividend Yield | % | 0.0 | 0.2 | - |
BH.IMMUN&BIO LUPIN |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
LUPIN Mar-23 |
BH.IMMUN&BIO/ LUPIN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 799 | 6.5% | |
Low | Rs | 21 | 583 | 3.5% | |
Sales per share (Unadj.) | Rs | 10.3 | 365.8 | 2.8% | |
Earnings per share (Unadj.) | Rs | -3.9 | 9.8 | -39.2% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 29.2 | -13.0% | |
Dividends per share (Unadj.) | Rs | 0 | 4.00 | 0.0% | |
Avg Dividend yield | % | 0 | 0.6 | 0.0% | |
Book value per share (Unadj.) | Rs | 20.4 | 270.7 | 7.5% | |
Shares outstanding (eoy) | m | 43.18 | 454.98 | 9.5% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 1.9 | 185.2% | |
Avg P/E ratio | x | -9.4 | 70.2 | -13.4% | |
P/CF ratio (eoy) | x | -9.5 | 23.7 | -40.1% | |
Price / Book Value ratio | x | 1.8 | 2.6 | 69.3% | |
Dividend payout | % | 0 | 40.7 | -0.0% | |
Avg Mkt Cap | Rs m | 1,561 | 314,381 | 0.5% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 30,872 | 0.5% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 166,417 | 0.3% | |
Other income | Rs m | 11 | 1,509 | 0.7% | |
Total revenues | Rs m | 457 | 167,926 | 0.3% | |
Gross profit | Rs m | -161 | 17,206 | -0.9% | |
Depreciation | Rs m | 2 | 8,807 | 0.0% | |
Interest | Rs m | 71 | 2,743 | 2.6% | |
Profit before tax | Rs m | -223 | 7,165 | -3.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 2,688 | -2.1% | |
Profit after tax | Rs m | -166 | 4,477 | -3.7% | |
Gross profit margin | % | -36.0 | 10.3 | -348.4% | |
Effective tax rate | % | 25.3 | 37.5 | 67.4% | |
Net profit margin | % | -37.3 | 2.7 | -1,386.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 124,513 | 0.3% | |
Current liabilities | Rs m | 940 | 92,654 | 1.0% | |
Net working cap to sales | % | -130.6 | 19.1 | -682.0% | |
Current ratio | x | 0.4 | 1.3 | 28.3% | |
Inventory Days | Days | 85 | 26 | 325.8% | |
Debtors Days | Days | 1,135 | 98 | 1,155.3% | |
Net fixed assets | Rs m | 1,262 | 103,490 | 1.2% | |
Share capital | Rs m | 432 | 910 | 47.5% | |
"Free" reserves | Rs m | 450 | 122,246 | 0.4% | |
Net worth | Rs m | 882 | 123,156 | 0.7% | |
Long term debt | Rs m | 0 | 275 | 0.0% | |
Total assets | Rs m | 1,620 | 228,003 | 0.7% | |
Interest coverage | x | -2.2 | 3.6 | -59.6% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 0.3 | 0.7 | 37.7% | |
Return on assets | % | -5.9 | 3.2 | -186.7% | |
Return on equity | % | -18.9 | 3.6 | -518.9% | |
Return on capital | % | -17.2 | 8.0 | -214.8% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 14.5 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 65 | NA | - | |
Fx inflow | Rs m | 0 | 48,057 | 0.0% | |
Fx outflow | Rs m | 65 | 21,752 | 0.3% | |
Net fx | Rs m | -65 | 26,306 | -0.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 18,972 | 0.6% | |
From Investments | Rs m | 5 | -12,868 | -0.0% | |
From Financial Activity | Rs m | -147 | -3,373 | 4.4% | |
Net Cashflow | Rs m | -34 | 2,732 | -1.2% |
Indian Promoters | % | 59.3 | 46.7 | 126.8% | |
Foreign collaborators | % | 0.0 | 0.3 | - | |
Indian inst/Mut Fund | % | 0.0 | 46.1 | - | |
FIIs | % | 0.0 | 18.3 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 53.0 | 76.9% | |
Shareholders | 35,313 | 280,248 | 12.6% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES DR. REDDYS LAB CIPLA SUN PHARMA ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | Lupin | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.03% | 0.45% | 0.58% |
1-Month | 0.96% | 4.16% | 3.13% |
1-Year | 34.11% | 113.03% | 55.61% |
3-Year CAGR | -18.83% | 11.83% | 13.89% |
5-Year CAGR | 30.15% | 16.96% | 21.73% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the Lupin share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of Lupin the stake stands at 47.0%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of Lupin.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
Lupin paid Rs 4.0, and its dividend payout ratio stood at 40.7%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of Lupin.
For a sector overview, read our pharmaceuticals sector report.
Indian share markets ended the mock trading session on a positive note tracking strong global peers and FII inflows.